SYNIMMUNE is a biotechnology company dedicated to the development of mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. Its product candidate FLYSYN is an antibody for acute myeloid leukemia.